FULC

Losmapimod

Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 2

Exp Date

Q2 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)  - Phase 2 

  • ClinicalTrial.gov (NCT04003974): Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)


WHAT IS THE NEXT CATALYST EVENT?

  • Full Phase 2 Data 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q2 2021


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds.

Updated by JM 

FULC, Fulcrum Therapeutics, Losmapimod, Facioscapulohumeral Muscular Dystrophy (FSHD)

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon